The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Antibody research reagents: Market survey data now available

by

The research reagent landscape is changing continuously and keeping up to date on all the significant occurrences takes time, connections, and objectivity. As such, for the past several years, Pivotal Scientific has observed, assessed and compiled an annual Antibody Market Report which gives new ideas and fresh insights about the market over the previous year and indicates how companies can grow in such a competitive market.

Within the report, the State of the Industry survey contains detailed information on the research reagent marketplace from the perspective of key distributors and manufacturers. This is Pivotal Scientific’s fourth yearly survey to better understand the research reagent industry. Once again, our respondents were separated into life science reagent manufacturers, and life science reagent distributors. Questions were focused on key areas of the reagent industry, sales & marketing, logistics, mergers & acquisitions, and product validation.

Key findings:

  • The majority of companies polled reported increasing sales during 2019. As a result, respondents were optimistic, predicting further sales increases and market growth in 2020. This confidence resulted in many distributors considering hiring more staff or opening more offices, although manufacturers displayed a little more caution by limiting expansion compared to previous years.
  • The Asian market continues to expand, with more products from China being distributed by respondents, and China and Japan becoming a bigger source of revenue for our manufacturers. Conversely, the UK appears to be a smaller source of revenue for our polled manufacturers in 2019. This could be due to worries over Brexit reducing science funding and/or spending. The US still dominates the market, being a major supplier of products to distributors and a major source of revenue to manufacturers. To take advantage of this large market, most manufacturers who responded are either based in the US or have a US office.
  • The consensus between distributors and manufacturers is that product quality matters most to their customers, while the main market opportunities are thought to be associated with antibodies and kits. The research area generating the most interest continues to be cancer, and their key competitors unsurprisingly are Abcam, Thermo Fisher Scientific, Bio-Techne and BD Biosciences.
  • The respondents acknowledged the industry could still be doing more to improve product validation. Whilst levels of validation vary between distributors, manufacturers appear to be making a concerted effort to increase validation standards.
  • We can expect further mergers and acquisitions to take place in 2020. Many companies have stated an interest in either buying or selling in 2020, especially amongst the polled distributors.

Need more details?

A more detailed analysis of the results of our survey and industry insights can be found in the Pivotal Scientific Antibody Market Report 2020.

First study results for anti-SARS-CoV-2 antibody LY-CoV555

by

On September 16, 2020, Eli Lilly and Company announced proof of concept data from an interim analysis of the Phase 2 BLAZE-1 clinical trial (NCT04427501) of LY-CoV555 (also known as LY3819253), an anti-SARS-CoV-2 IgG1 antibody. The randomized, double-blind, placebo-controlled study included 4 arms (placebo, 700 mg, 2800 mg, and 7000 mg administered intravenously (IV)), and enrolled mild-to-moderate recently diagnosed COVID-19 patients. Treatment is provided in an outpatient setting. The study was initiated on June 17, 2020 and has an estimated primary completion date of September 20, 2020.

  • The prespecified primary endpoint, change from baseline in viral load at day 11, was met at the 2800 mg dose level, but not the others. Additional analyses of viral data demonstrated that LY-CoV555 improved viral clearance at an earlier time point (day 3) and reduced the proportion of patients with persistently high viral load at later time points. Most patients, including those receiving placebo, demonstrated near complete viral clearance by day 11.
  • Analysis of pooled data from all dose groups indicated the rate of hospitalizations and ER visits was 1.7% (5/302) for LY-CoV555 vs. 6% (9/150) for placebo. Across all treatment groups (including placebo), no patients progressed to mechanical ventilation or died.
  • Viral RNA sequencing revealed putative LY-CoV555-resistance variants in placebo and all treatment arms. The rate of resistance variants was numerically higher in treated patients (8 percent) versus placebo (6 percent).
  • LY-CoV555 was well-tolerated, with no drug-related serious adverse events reported. Treatment emergent adverse events were similar across all dose groups and comparable to placebo.

Details for the BLAZE-1 study were updated on August 21, 2020 to include an experimental treatment arm comprising LY3819253 + LY3832479 (also known as LY-CoV016) administered IV.  LY-CoV016 binds a different epitope in the SARS-CoV-2 spike region compared to LY-CoV555. Across all treatment arms, the trial will enroll an estimated 800 participants.

Summary data for all anti-SARS-CoV-2 antibodies in clinical studies can be found here.

Fighting the Forever-war Against Infectious Diseases

by

Author: Nick Hutchinson, Mammalian Cell Culture, Business Steering Group Lead, FUJIFILM Diosynth Biotechnologies (nick.hutchinson@fujifilm.com)

The COVID-19 crisis has had a devastating impact on populations across the world and caused the death of hundreds of thousands of people. The Antibody Society spoke to Dr. Jacob Glanville, CEO and President of Distributed Bio, Inc. to learn how his company has approached the development of new antibody therapeutics against the SARS-CoV-2 Coronavirus. He described how the crisis has stimulated innovation that may revolutionize the way we approach antibody discovery and development once the current pandemic is under control.

Dr Glanville explained, “The problem, when we think of every major outbreak, such as Ebola, SARS, MERS, Swine Flu, Avian Flu, is that the time it takes to develop a new drug is too long compared to the speed with which we need it. De novo discovery is too slow.”

To develop antibody therapeutics against COVID-19 as quickly as possible, Distributed Bio identified anti-SARS antibodies from almost 20 years ago that researchers had already shown would neutralize the SARS virus in vitro, protect mice from lethal challenge, and had known crystal structures. These antibodies have been studied extensively but were eventually too late to have an impact on the SARS crisis of 2003. It was Glanville’s idea to take advantage of the detailed functional research already performed on these antibodies and, try to retrofit them to bind to the new version of their original target the virus SARS-CoV-2. For this purpose, Distributed Bio applied their Tumbler technology, a computationally-guided antibody optimization method, capable of producing a library of billions of variants of individual antibodies exploring variations of all six complementarity-determining regions simultaneously.

“The novel coronavirus has around 74% homology in identity with the SARS receptor binding domain. I knew exactly how similar they were to the novel coronavirus as we had crystal structures of the SARS epitope. I believed that if we took five anti-SARS antibodies, there was going to be a pretty good chance that we would be able to adapt them to be a potent medicine against COVID-19,” said Glanville. “We already knew that they had the correct function, that they bound the right epitope in the right orientation with the right elbow angles. I believed that we could optimize them and enhance their affinity by making billions of versions of the antibodies within the library,” he continued.

According to Glanville, this is crucially important because historically, with outbreaks such as Ebola, the first antibodies launched were essentially prototypes with low potency or had inferior characteristics such as poor thermostability. It was the best-in-class not the first antibody that was successful, ultimately.

Distributed Bio were able to adapt all five antibodies in just nine weeks, a testament to the remarkable speed of these novel technologies. They sent a set of the most promising candidates to five laboratories which independently confirmed their ability to bind to the new SARS-CoV-2. The company then selected the two most potent antibodies for in-vivo testing, and two laboratories confirmed independently that both candidates protected healthy, as well as immuno-compromised animals using hamster models.

[Read more…]

AIRR-C Special Event – Response to COVID-19: Videos are Live

by

The AIRR Community held a successful virtual event showcasing how AIRR-sequencing data can be leveraged to inform the Biology of COVID-19.

The AIRR Community held a successful event showcasing how AIRR-sequencing data can be leveraged to inform the Biology of COVID-19. 3 days, 8 speakers, 5 moderated panel discussions, and 355 attendees from 25 countries made for a meaningful discussion.

Check out the AIRR Youtube Channel for the recorded talks.

 

AIRR Community 3 Day Special Event – Response to COVID-19 Talks Start Today!

by

The 3 day AIRR Community Special Event – Response to COVID-19 starts today. Join the Community and learn more about Leveraging AIRR-sequencing Data to Inform the Biology of COVID-19. Contact meetings@AIRRC.antibodysociety.org to register. Visit the event page for the complete program.

Follow the event on Twitter #airrcovid.